New US and EU guidelines recommend Gilead’s BIKTARVY® (bictegravir / emtricitabine / tenofovir alafenamide)

In October 2018, the US Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) released new guidelines for the management of people living with HIV (PLHIV). Both guidelines incorporated Gilead’s once-daily, single tablet regimen (STR), BIKTARVY®, which comprises an integrase strand transfer inhibitor [INSTI; bictegravir (BIC)] combined with two nucleoside reverse transcriptase inhibitors [NRTIs; emtricitabine (FTC) and tenofovir alafenamide (TAF)].1-3